A Study of ZL-1310 in Participants With Selected Solid Tumors (NCT06885281)

🧪 Interventions in This Study

• ZL-1310 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (23 Sites)

• University of California San Francisco/Helen Diller Family Comprehensive Cancer Center — San Francisco, California
• OSF St. Francis Medical Center — Peoria, Illinois
• Karmanos Cancer Center — Detroit, Michigan
• Memorial Sloan-Kettering Cancer Center — New York, New York
• University Hospitals Cleveland Medical Center — Cleveland, Ohio
• Fox Chase Cancer Center — Philadelphia, Pennsylvania
• SCRI OP (Oncology Partners) — Nashville, Tennessee
• Texas Oncology / Sammons Cancer Center — Dallas, Texas
• The University of Texas M. D. Anderson Cancer Center — Houston, Texas
• Texas Oncology - Central South — McAllen, Texas
• Virginia Cancer Specialists — Fairfax, Virginia
• Virginia Oncology Associates — Norfolk, Virginia
• Beijing Cancer Hospital — Beijing, Beijing Municipality
• Beijing Gobroad Hospital — Beijing, Beijing Municipality
• The First Affiliated Hospital of Xiamen University — Xiamen, Fujian
• Sun Yat-sen University Cancer Center — Guangzhou, Guangdong
• The First Affiliated Hospital, Sun Yat-sen University — Guangzhou, Guangdong
• Harbin Medical University Cancer Hospital — Harbin, Heilongjiang
• Hunan Cancer Hospital — Changsha, Hunan
• Jilin Cancer Hospital — Changchun, Jilin
• Fudan University Shanghai Cancer Center — Shanghai, Shanghai Municipality
• Huashan Hospital Fudan University — Shanghai, Shanghai Municipality
• Shanghai Pulmonary Hospital — Shanghai, Shanghai Municipality

📞 Contact the Study Coordinator

Phone: (650) 360-1601

Email: Zailab_1310-002_StudyTeam@zailaboratory.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Solid Tumors

• Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors — Basking Ridge, New Jersey
• Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours — Edmonton, Alberta
• Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) — Santa Monica, California
• A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial — Porto Alegre, Rio Grande do Sul
• Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors — Los Angeles, California
• Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors — Phoenix, Arizona

Explore by condition: All Solid Tumors clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.